Effect of Interleukin-6 Receptor Inhibition by Tocilizumab on Platelet Activation and Markers of Thrombus Formation: A Substudy of the ASSAIL-MI Trial

Key Points

• This research examines how tocilizumab affects platelet activation and thrombus formation in patients with ST-segment-elevation myocardial infarction.
• Substudy of the ASSAIL-MI Trial
• Analyzed platelet activation and coagulation markers
• Monitored changes in markers over time
• Tocilizumab significantly reduced platelet activation and coagulation markers, indicating a positive effect on thrombus formation.
• A notable rise in TF was observed, suggesting a potential side effect of tocilizumab that requires further investigation.